Dashboard
1
Company has a low Debt to Equity ratio (avg) at times
2
Healthy long term growth as Net Sales has grown by an annual rate of 45.12%
3
The company declared negative results in Mar'25 after positive results in Dec'24
4
With ROE of 18.93%, it has a very expensive valuation with a 21.84 Price to Book Value
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
SEK 13,580 Million (Small Cap)
115.00
NA
0.00%
-0.44
18.66%
16.25
Revenue and Profits:
Net Sales:
284 Million
(Quarterly Results - Jun 2025)
Net Profit:
53 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-42.09%
0%
-42.09%
6 Months
-27.35%
0%
-27.35%
1 Year
-49.0%
0%
-49.0%
2 Years
4.49%
0%
4.49%
3 Years
116.49%
0%
116.49%
4 Years
420.68%
0%
420.68%
5 Years
142.48%
0%
142.48%
BONESUPPORT HOLDING AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
45.12%
EBIT Growth (5y)
32.98%
EBIT to Interest (avg)
-33.59
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.35
Sales to Capital Employed (avg)
1.23
Tax Ratio
20.69%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
9.90%
ROE (avg)
12.58%
Valuation key factors
Factor
Value
P/E Ratio
115
Industry P/E
Price to Book Value
21.84
EV to EBIT
78.53
EV to EBITDA
78.53
EV to Capital Employed
34.61
EV to Sales
16.09
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
44.07%
ROE (Latest)
18.93%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
Bullish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
284.40
219.80
29.39%
Operating Profit (PBDIT) excl Other Income
66.30
29.70
123.23%
Interest
0.90
0.20
350.00%
Exceptional Items
-2.80
0.00
Consolidate Net Profit
53.10
27.40
93.80%
Operating Profit Margin (Excl OI)
233.00%
135.20%
9.78%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 29.39% vs 56.55% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 93.80% vs 426.92% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
898.70
591.10
52.04%
Operating Profit (PBDIT) excl Other Income
157.70
32.30
388.24%
Interest
2.30
3.10
-25.81%
Exceptional Items
0.00
0.00
Consolidate Net Profit
133.80
245.00
-45.39%
Operating Profit Margin (Excl OI)
163.50%
37.50%
12.60%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 52.04% vs 79.77% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -45.39% vs 459.24% in Dec 2023
About BONESUPPORT HOLDING AB 
BONESUPPORT HOLDING AB
Pharmaceuticals & Biotechnology
Bonesupport Holding AB is a Sweden-based orthobiologics company. It develops and commercialize injectable bioceramic bone graft substitutes which remodel to host bone and have the capability to elute drugs directly into the bone void. The marketed synthetic bone graft substitutes are CERAMENT BVF, CERAMENT G and CERAMENT V, which are based on the CERAMENT technology platform. The products are commercially available in Europe and the United States, as well as in India, Malaysia, Oman and Singapore. The products are developed to treat patients with fractures and bone voids caused by trauma and related surgery, as well as caused by infection or diseases, such as chronic osteomyelitis, revision arthroplasty and infected diabetic foot.
Company Coordinates 
Company Details
Scheelevagen 19 , LUND None : 223 70
Registrar Details






